EFFICACY OF MOMETASONE FUROATE NASAL SPRAY IN THE TREATMENT OF PATIENTS WITH POST-VIRAL RHINOSINUSITIS
ON THE BACKGROUND OF PERSISTENT ALLERGIC RHINITIS WITH SENSITIZATION TO HOUSE DUST MITES

Gogunska I, Zabolotna D, Smagina T, Nesterchuk V

State Institution «O. S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Sciences of Ukraine»;
email: amtc@kndio.kiev.ua

Abstract

Relevance: Acute rhinosinusitis and allergic rhinitis are widespread diseases and require adequate and effective treatment. According to the recommendations of the latest guidelines, the use of intranasal corticosteroids is recommended for the treatment of allergic rhinitis and post-viral rhinosinusitis. Since one locus morbi (nasal cavity and paranasal sinuses) is involved in the pathological process, it should be expected that the course of postviral sinusitis (PVRS) with concomitany allergic rhinitis and the efficacy of treatment of patients with this pathology may have certain peculiarities.

Objective: to evaluate the efficacy of mometasone furoate nasal spray (nasonex) 200 mcg per day in the treatment of patients with post-viral rhinosinusitis (PVRS) and concomitant persistent allergic rhinitis (PAR) with sensitization to house dust mites.

Materials and Methods: Adult patients with post-viral rhinosinusitis (PVRS) received mometasone furoate nasal spray (nasonex) 200 mcg per day for 15 days. The first group included patients with PVRS without accompanying allergic rhinitis (30 patients). The second group included patients with PVRS on the background of persistent allergic rhinitis (PAR) with sensitization to house dust mites (30 patients). The effectiveness of the treatment was evaluated based on the assessment of subjective and objective signs of PVRS and PAR, the assessment of the overall severity of PVRS and PAR symptoms on the VAS scale, and the assessment of the patient’s condition on the scale of the general clinical condition (CGI).

Results and Discussion: Nasal congestion in patients of the first group with concomitant PAR was significantly higher at the beginning of treatment. In both groups of the study, a pronounced and rapid regression of clinical manifestations of PVRS was observed, the indicators of the quality of life of the patients improved. There was a trend towards more pronounced dynamics of objective and subjective symptoms in the second group of patients, which, however, was not statistically significant. Adverse events in the study were predictable and mild in severity.

Conclusions: Mometasone furoate has been well tolerated with a favorable safety profile in the treatment of patients with post-viral rhinosinusitis and concomitant persistent allergic rhinitis with sensitization to house dust mites.

Keywords: mometasone furoate, post-viral rhinosinusitis, persistent allergic rhinitis.